The twice-yearly injectable, which significantly reduces HIV incidence compared with oral regimens, has high adherence and manageable adverse effects.
NEHA SHETH PANDIT, PHARMD, AAHIVP
Advertisement
Sheth Pandit is professor and co-vice chair for research and scholarship in the Department of Practice, Sciences, and Health Outcomes Research at the University of Maryland School of Pharmacy.
Articles by NEHA SHETH PANDIT, PHARMD, AAHIVP
Novel modes of delivery are imperative to improve HIV suppression and prevent transmission.
Advertisement
Latest Updated Articles
Prospective Game Changer: Lenacapavir for HIV Preexposure ProphylaxisPublished: January 12th 2026 | Updated:
- Alternative Antiretroviral Medication Delivery Systems Emerge to Treat, Prevent HIV Infection
Published: December 6th 2019 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Company Launches Mold Panel to Accelerate Diagnosis of Invasive Fungal Infections
2
Donning and Doffing PPE for High-Consequence Infectious Disease Treatment
3
Valneva Withdraws its IND and BLA for its Chikungunya Vaccine
4
Lab Safety Considerations In Dealing With High-Consequence Infectious Disease
5